HighTower Advisors LLC Takes $139,000 Position in Telomir Pharmaceuticals, Inc. $TELO

HighTower Advisors LLC bought a new position in shares of Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 43,000 shares of the company’s stock, valued at approximately $139,000. HighTower Advisors LLC owned approximately 0.14% of Telomir Pharmaceuticals as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Nuveen Asset Management LLC purchased a new stake in shares of Telomir Pharmaceuticals in the fourth quarter valued at about $103,000. Barclays PLC lifted its position in Telomir Pharmaceuticals by 326.9% during the fourth quarter. Barclays PLC now owns 29,959 shares of the company’s stock valued at $123,000 after purchasing an additional 22,941 shares during the last quarter. Northern Trust Corp raised its stake in shares of Telomir Pharmaceuticals by 211.5% during the fourth quarter. Northern Trust Corp now owns 151,628 shares of the company’s stock worth $625,000 after acquiring an additional 102,948 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Telomir Pharmaceuticals by 279.4% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,699 shares of the company’s stock worth $44,000 after buying an additional 7,879 shares during the period. Finally, Wells Fargo & Company MN increased its stake in shares of Telomir Pharmaceuticals by 458.3% in the fourth quarter. Wells Fargo & Company MN now owns 10,044 shares of the company’s stock worth $41,000 after buying an additional 8,245 shares during the period.

Telomir Pharmaceuticals Trading Up 5.1%

Shares of Telomir Pharmaceuticals stock opened at $1.24 on Friday. The company’s fifty day simple moving average is $1.54 and its two-hundred day simple moving average is $2.45. The company has a market cap of $40.03 million, a P/E ratio of -2.30 and a beta of -0.73. Telomir Pharmaceuticals, Inc. has a 12-month low of $1.12 and a 12-month high of $8.40.

Telomir Pharmaceuticals (NASDAQ:TELO) last released its earnings results on Thursday, August 14th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.09). Analysts predict that Telomir Pharmaceuticals, Inc. will post -0.4 EPS for the current fiscal year.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.